U.S. Markets open in 49 mins.

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
27.23+0.24 (+0.89%)
At close: 4:00PM EDT
People also watch
  • Dear Mr. Cramer- please say to sell this stock and you don't like it- I want it to go up again as things you usually do when you blast them-just like last week
  • Barron's expects Exel will beat estimates.
  • Must read on page 5/24 Investor Update Feb 2017 from Roche Hldg.

    "in May and October respectively, market uptake in the US has been strong. Cotellic (CHF 45 million) plus Zelboraf for BRAF-mutated metastatic melanoma showed good sales uptake, especially in major markets such as France and the US."

  • Part 2 from William Blair Bullish call:

    Particularly considering this new amendment spells out quite the win/win scenario for the biotech firm from the analyst's eyes, who underscores an advantageous one-two punch of better revenue potential meets lowered cost responsibility, the analyst reiterates an Outperform rating on the stock without indicating a price target.
    Overall, "[…] Exelixis’s cost responsibility will go down as more drugs are being combined with Cotellic. Based on Bloomberg Symphony data, the monthly wholesale acquisition costs (WAC) of Cotellic, Zelboraf, and Tecentriq are roughly $6,500, $10,800, and $12,400, respectively. We note that the actual revenue recognized in the profits and losses will likely be lower due to the negative impact of discounts and rebates. As a result, we see a 33% potential increase (Cotellic’s $6,500 and average price of Cotellic and Zelboraf of $8,650) in revenue recognition, assuming similar gross-to-net adjustments across products. In addition, while still in Phase III development, the triple combination (Cotellic, Zelboraf, and Tecentriq) has an average monthly WAC of $9,900 and could contribute a 52% increase in revenue recognition to Cotellic monotherapy," Hsieh surmises.
  • Today's news demonstrates that this company is doing everything right.

    They have great drugs and right strategy. They have established not only developmental partnerships but also Commercialization partnerships with right partners.

    While no one can guarantee the future, but looks like EXEL is company with extremely bright long term horizon (unless a buy out happens..).
  • News leaked yesterday. Now we push toward that $30 mark. More revenue coming from re negotiating the deal with Genentech. Boom Buda Bang! Stronger buy!
  • Another new day full of possibilities for EXEL!! Also option expiration...
  • Bullish call on EXEL

    "As such, the analyst sees an approximate 33% rise in revenue recognition for the Cotellic collaboration as far as profits and losses starting this month. Gearing up for chances for greater upside with cancer immunotherapy drug meta Tecentriq continuing in combination trials, Hsieh sees a gilded road ahead for Exelixis."
  • Lmfao @ anonymous
  • Another terrible week for EXEL...time to buy TMZ....uh i mean TNA.....no wait TNT..#$%$ what was that great stock that I got a great tip.on....
  • cramer says stay away which means 'buy"
  • This stock is ready to pop. MM's are trying to keep the lid on. $27.43 may just happen today.
  • Anonymous I think you should buy some more TZA. EXEL is just a terrible stock, you wouldn't want it - those of us that are longs are only up 225% so far this year.
  • I am seeing $27.43 next level up to hit, than $27.73. Not sure that we can move there this early in the day. But if we can get some momentum late after noon we can have a great close.
  • EXEL was at $20 in June and $25+ in July, maybe $30+ in August!!! I am ver confident and will add the dips... GLTA!!
  • Approaching $35. IMO
  • Anonymous is always quiet on Green EXEL days..
  • disregard anonymous. I heard from him on Omer. he is always wrong and spewing misinformation.
  • Exel is one of the few companies on Gilead's radar according to many analysts!
  • Something is very weird with the trades today someone is keeping the lid on at $27.19. Why? Not sure, possible consolidation of shares. The pattern is really tight.